Of 1335 phenotypes in the BioVU biobank, 46 were significantly associated with the PRS for cannabis use disorder (p<3·74 × 10−5; figure 3, appendix p 18). The phenotype groups with the most abundant associations were mental disorders (n=12), the strongest associations being with tobacco use disorder (cases 5280, OR 1·18, 95% CI 1·13–1·23, SE 0·02; p=2·66 × 10−27) and substance use disorders (cases 6155, OR 1·18, SE 0·01, 95% CI 1·16–1·20; p=1·24 × 10−30), mood disorders (cases 9588, OR 1·09, SE 0·01, 95% CI 1·07–1·11; p=2·38 × 10−12) and suicidal ideation or attempt (cases 689, OR 1·27, SE 0·04, 95% CI 1·17–1·37; p=1·81 × 10−9); respiratory diseases (n=12), such as respiratory failure (cases 4485, OR 1·11, SE 0·02, 95% CI 1·07–1·15; p=4·45 × 10−10) or chronic airway obstruction (cases 4436, OR 1·13, SE 0·02, 95% CI 1·09–1·18; p=5·64 × 10−14); endocrine or metabolic conditions (n=3), such as disorders of fluid (cases 12 562, OR 1·06, SE 0·01, 95% CI 1·04–1·08; p=5·77 × 10−8); infectious diseases (n=4), such as viral hepatitis (cases 135, OR 1·3, SE 0·03, 95% CI 1·23–1·38; p=3·34
